Factor v and thrombotic disease -: Description of a janus-faced protein

被引:158
作者
Nicolaes, GAF [1 ]
Dahlbäck, B [1 ]
机构
[1] Lund Univ, Wallenberg Lab, Malmo Univ Hosp, Div Clin Chem,Dept Lab Med, Malmo, Sweden
关键词
factor V; activated protein C resistance; factor V-Leiden; thrombosis; protein C;
D O I
10.1161/01.ATV.0000012665.51263.B7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The generation of thrombin by the prothrombinase complex constitutes an essential step in hemostasis, with thrombin being crucial for the amplification of blood coagulation, fibrin formation, and platelet activation. In the prothrombinase complex, the activated form of coagulation factor V (FVa) is an essential cofactor to the enzyme-activated factor X (FXa), FXa being virtually ineffective in the absence of its cofactor. Besides its procoagulant potential, intact factor V (FV) has an anticoagulant cofactor capacity functioning in synergy with protein S and activated protein C (APC) in APC-catalyzed inactivation of the activated form of factor VIII. The expression of anticoagulant cofactor function of FV is dependent on APC-mediated proteolysis of intact FV. Thus, FV has the potential to function in procoagulant and anticoagulant pathways, with its functional properties being modulated by proteolysis exerted by procoagulant and anticoagulant enzymes. The procoagulant enzymes factor Xa and thrombin are both able to activate circulating FV to FVa, The activity of FVa is, in turn, regulated by APC together with its cofactor protein S. In fact, the regulation of thrombin formation proceeds primarily through the upregulation and downregulation of FVa cofactor activity, and failure to control FVa activity may result in either bleeding or thrombotic complications. A prime example is APC resistance, which is the most common genetic risk factor for thrombosis. It is caused by a single point mutation in the FV gene (factor V-Leiden) that not only renders FVa less susceptible to the proteolytic inactivation by APC but also impairs the anticoagulant proper-ties of FV. This review gives a description of the dualistic character of FV and describes the gene-gene and gene-environment interactions that are important for the involvement of FV in the etiology of venous thromboembolism.
引用
收藏
页码:530 / 538
页数:9
相关论文
共 107 条
[1]  
Alhenc-Gelas M, 1999, THROMB HAEMOSTASIS, V81, P193
[2]   A POPULATION-BASED PERSPECTIVE OF THE HOSPITAL INCIDENCE AND CASE-FATALITY RATES OF DEEP-VEIN THROMBOSIS AND PULMONARY-EMBOLISM - THE WORCESTER DVT STUDY [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
PATWARDHAN, NA ;
JOVANOVIC, B ;
FORCIER, A ;
DALEN, JE .
ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (05) :933-938
[3]   PROTEIN-S AS AN IN-VIVO COFACTOR TO ACTIVATED PROTEIN-C IN PREVENTION OF MICROARTERIAL THROMBOSIS IN RABBITS [J].
ARNLJOTS, B ;
DAHLBACK, B .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (05) :1987-1993
[4]   ANTITHROMBOTIC EFFECTS OF ACTIVATED PROTEIN-C AND PROTEIN-S IN A RABBIT MODEL OF MICROARTERIAL THROMBOSIS [J].
ARNLJOTS, B ;
DAHLBACK, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) :937-941
[5]   Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors [J].
Baglin, C ;
Brown, K ;
Luddington, R ;
Baglin, T .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (04) :764-768
[6]   A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype [J].
Bernardi, F ;
Faioni, EM ;
Castoldi, E ;
Lunghi, B ;
Castaman, G ;
Sacchi, E ;
Mannucci, PM .
BLOOD, 1997, 90 (04) :1552-1557
[7]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[8]   Genetic aspects of venous thrombosis [J].
Bertina, RM .
EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 95 (02) :189-192
[9]   Secretable human platelet-derived factor V originates from the plasma pool [J].
Camire, RM ;
Pollak, ES ;
Kaushansky, K ;
Tracy, PB .
BLOOD, 1998, 92 (09) :3035-3041
[10]   Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V leiden) and His1299Arg substitutions in factor V [J].
Castaman, G ;
Lunghi, B ;
Missiaglia, E ;
Bernardi, F ;
Rodeghiero, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (02) :257-261